Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs BGNE

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:BGNE)

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

PR Newswire June 30, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Accesswire June 29, 2023

BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of BeiGene Stockholders and Encourages Investors to Contact the Firm

Business Wire June 26, 2023

ROSEN, A Top Ranked Law Firm, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

Newsfile June 26, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Accesswire June 26, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

Newsfile June 24, 2023

BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

PR Newswire June 23, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Accesswire June 20, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Accesswire June 18, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Accesswire June 17, 2023

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)

Business Wire June 16, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Accesswire June 16, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm

Business Wire June 15, 2023

BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

Business Wire June 15, 2023

BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics

Business Wire June 15, 2023

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

Business Wire June 9, 2023

Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults

Canada NewsWire May 30, 2023

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia

Business Wire May 30, 2023

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Business Wire May 25, 2023

BeiGene to Present at Upcoming Investor Conferences

Business Wire May 24, 2023